Category: MedtronicSyndicate content

Credit agencies lower Medtronic's rating post-Covidien merger

January 28, 2015 by Brad Perriello

Credit agencies Standard & Poor's and Moody's lowered their ratings as promised on Medtronic after it took out a massive debt package to finance its $50 billion acquisition of Covidien.

Credit agencies lower Medtronic's rating post-Covidien merger

MDT wins HDE for Enterra II | Regulatory news for the week of January 26, 2015

January 27, 2015 by MassDevice

Here's a look at some of the top regulatory stories for medical device companies this week: Medtronic wins HDE for Enterra II neurostim device; FDA officially clears Integra's Puerto Rico plant; Nevro surges on Senza approvable letter from FDA; mHealth: AliveCor wins CE Mark for new afib algorithm; FDA warns against pediatric use of bone growth proteins

Medtronic wins HDE for Enterra II neurostim device

January 23, 2015 by Brad Perriello

Medtronic buyout complete, Covidien closes Stellarex deal with Spectranetics

January 27, 2015 by Brad Perriello

Covidien and Spectranetics close the $30 million deal for the Stellarex drug-eluting balloon, following the close yesterday of Medtronic's $50 billion acquisition of Covidien.

Medtronic buyout complete, Covidien closes Stellarex deal with Spectranetics

UPDATE: Medtronic closes $50B Covidien buyout

January 26, 2015 by Brad Perriello

The largest merger in medtech history closes the same day that the Irish High Court sanctions the $49.9 billion union of Medtronic and Covidien.

UPDATE: Medtronic closes $50B Covidien buyout

Medtronic wins HDE for Enterra II neurostim device

January 23, 2015 by Brad Perriello

Medtronic wins a humanitarian device exemption for its Enterra II neurostimulation implant for treating the stomach disorder gastroparesis.

Medtronic wins HDE for Enterra II neurostim device

Medtronic (NYSE:MDT) today said it won a humanitarian device exemption for its Enterra II device, a neurostimulation implant designed to treat the stomach disorder gastroparesis.

FDA warns against pediatric use of bone growth proteins

January 22, 2015 by Mark Hollmer

The FDA warns against using bone-growth proteins in patients under 18 who have bone growth defects, citing the risk of excess bone growth and other potential problems.

FDA warns on pediatric use of bone growth proteins

The FDA this week warned healthcare providers against using 2 types of bone-growth materials in patients under age 18 who have bone growth defects.

Covidien's Q1 earnings top estimates

January 22, 2015 by Brad Perriello

Covidien issues its final quarterly report as a standalone company, saying its fiscal 1st-quarter earnings beat expectations and it prepares for a $43 billion acquisition by Medtronic next week.

Covidien's Q1 earnings top estimates